STAT-1 mediates the stimulatory effect of IL-10 on CD14 expression in human monocytic cells

Journal of Immunology

Volumn 174, Issue 12, 2005, Pages 7823-7832

  Rahimi, Ali Akbar Rahim ^a   Gee, Katrina ^a   Mishra, Sasmita ^a   Lim, Wilfred ^a   Kumar, Ashok ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CD14 ANTIGEN; INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN HL 60; CYTOKINE PRODUCTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOCYTE; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 20444391740     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.12.7823     Document Type: Article

References (59)

1. Vieira, P., R. de Waal-Malefyt, M. N. Dang, K. E. Johnson, R. Kastelein, D. F. Fiorentino, J. E. deVries, M. G. Roncarolo, T. R. Mosmann, and K. W. Moore. 1991. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. USA 88: 1172-1176.
2. Moore, K. W., M. R. de Waal, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
3. Pestka, S., C. D. Krause, D. Sarkar, M. R. Walter, Y. Shi, and P. B. Fisher. 2004. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22: 929-979.
4. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, and A. O'Garra. 1991. 1L-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146: 3444-3451.
5. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174: 915-924.
6. Rousset, F., E. Garcia, T. Defrance, C. Peronne, N. Vezzio, D. H. Hsu, R. Kastelein, K. W. Moore, and J. Banchereau. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89: 1890-1893.
7. Del Prete, G., M. De Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150: 353-360.
8. Daftarian, P. M., A. Kumar, M. Kryworuchko, and F. Diaz-Mitoma. 1996. IL-10 production is enhanced in human T cells by IL-12 and 1L-6 and in monocytes by tumor necrosis factor-α. J. Immunol. 157: 12-20.
9. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174: 1549-1555.
10. Mocellin, S., M. C. Panelli, E. Wang, D. Nagorsen, and F. M. Marincola. 2003. The dual role of 1L-10. Trends Immunol. 24: 36-43.
11. +) B cells to secrete IgG1 and IgG3. J. Exp. Med. 179: 757-762.
12. Ishida, H., R. Hastings, J. Kearney, and M. Howard. 1992. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med. 175: 1213-1220.
13. Riley, J. K., K. Takeda, S. Akira, and R. D. Schreiber. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway: requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274: 16513-16521.
14. Weber-Nordt, R. M., J. K. Riley, A. C. Greenlund, K. W. Moore, J. E. Darnell, and R. D. Schreiber. 1996. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271: 27954-27961.
15. Finbloom, D. S., and K. D. Winestock. 1995. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes. J. Immunol. 155: 1079-1090.
16. 1NK4D by IL-10 contributes to inhibition of macrophage proliferation. J. Immunol. 164: 4607-4615.
17. O'Farrell, A. M., Y. Liu, K. W. Moore, and A. L. Mui. 1998. 1L-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 17: 1006-1018.
18. Berlato, C., M. A. Cassatella, I. Kinjyo, L. Gatto, A. Yoshimura, and F. Bazzoni. 2002. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168: 6404-6411.
19. Ding, Y., D. Chen, A. Tarcsafalvi, R. Su, L. Qin, and J. S. Bromberg. 2003. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 170: 1383-1391.
20. Gatto, L., C. Berlato, V. Poli, S. Tininini, I. Kinjyo, A. Yoshimura, M. A. Cassatella, and F. Bazzoni. 2004. Analysis of SOCS-3 promoter responses to interferon-γ. J. Biol. Chem. 279: 13746-13754.
21. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
22. Crawley, J. B., L. M. Williams, T. Mander, F. M. Brennan, and B. M. Foxwell. 1996. Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine. J. Biol. Chem. 271: 16357-16362.
23. Zhou, J. H., S. R. Broussard, K. Strle, G. G. Freund, R. W. Johnson, R. Dantzer, and K. W. Kelley. 2001. IL-10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate-2 and phosphatidylinositol 3′-kinase. J. Immunol. 167: 4436-4442.
24. Burfoot, M. S., N. C. Rogers, D. Watling, J. M. Smith, S. Pons, G. Paonessaw, S. Pellegrini, M. F. White, and I. M. Kerr. 1997. Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons. J. Biol. Chem. 272: 24183-24190.
25. Deane, J. A., and D. A. Fruman. 2004. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22: 563-598.
26. Pahan, K., M. Khan, and I. Singh. 2000. Interleukin-10 and interleukin-13 inhibit proinflammatory cytokine-induced ceramide production through the activation of phosphatidylinositol 3-kinase. J. Neurochem. 75: 576-582.
27. Lee, T. S., and L. Y. Chau. 2002. Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat. Med. 8: 240-246.
28. Lim, W., W. Ma, K. Gee, S. Aucoin, D. Nandan, F. Diaz-Mitoma, M. Kozlowski, and A. Kumar. 2002. Distinct role of p38 and c-Jun N-terminal kinases in IL-10-dependent and IL-10-independent regulation of the costimulatory molecule B7.2 in lipopolysaccharide-stimulated human monocytic cells. J. Immunol. 168: 1759-1769.
29. Gee, K., W. Lim, W. Ma, D. Nandan, F. Diaz-Mitoma, M. Kozlowski, and A. Kumar. 2002. Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-α in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression. J. Immunol. 169: 5660-5672.
30. Creery, D., J. B. Angel, S. Aucoin, W. Weiss, W. D. Cameron, F. Diaz-Mitoma, and A. Kumar. 2002. Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10. Clin. Diagn. Lab. Immunol. 9: 1212-1221.
31. Triantafilou, M., and K. Triantafilou. 2002. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23: 301-304.
32. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92: 7686-7689.
33. Lewis, T. S., P. S. Shapiro, and N. G. Ahn. 1998. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74: 49-139.
34. Lee, J. C., and P. R. Young. 1996. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J. Leukocyte Biol. 59: 152-157.
35. Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98: 13681-13686.
36. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 269: 5241-5248.
37. Ma, W., K. Gee, W. Lim, K. Chambers, J. B. Angel, M. Kozlowski, and A. Kumar. 2004. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide- stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J. Immunol. 172: 318-330.
38. Ma, W., W. Lim, K. Gee, S. Aucoin, D. Nandan, M. Kozlowski, F. Diaz-Mitoma, and A. Kumar. 2001. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J. Biol. Chem. 276: 13664-13674.
39. Dong, C., R. J. Davis, and R. A. Flavell. 2002. MAP kinases in the immune response. Annu. Rev. Immunol. 20: 55-72.
40. Turkson, J., D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276: 45443-45455.
41. Gao, H., R. F. Guo, C. L. Speyer, J. Reuben, T. A. Neff, L. M. Hoesel, N. C. Riedemann, S. D. McClintock, J. V. Sarma, R. N. Van, et al. 2004. Stat3 activation in acute lung injury. J. Immunol. 172: 7703-7712.
42. Lejeune, D., L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J. C. Renauld. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line: pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277: 33676-33682.
43. Triantafilou, M., and K. Triantafilou. 2002. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23: 301-304.
44. Ferrero, E., D. Jiao, B. Z. Tsuberi, L. Tesio, G. W. Rong, A. Haziot, and S. M. Goyert. 1993. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. USA 90: 2380-2384.
45. Oesterreicher, C., F. Pfeffel, D. Petermann, and C. Muller. 1995. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J. Hepatol. 23: 396-402.
46. Landmann, R., A. M. Reber, S. Sansano, and W. Zimmerli. 1996. Function of soluble CD14 in serum from patients with septic shock. J. Infect. Dis. 173: 661-668.
47. Nockher, W. A., R. Wigand, W. Schoeppe, and J. E. Scherberich. 1994. Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus. Clin. Exp. Immunol. 96: 15-19.
48. Higuchi, Y., N. Hijiya, K. Matsuura, A. Yasui, T. Uchida, and S. Yamamoto. 2002. Mouse soluble CD14 truncated at amino acid 71 in transgenic mice: preventive effect on endotoxin-mediated toxic shock. Pathobiology 70: 103-114.
49. Maliszewski, C. R. 1991. CD14 and immune response to lipopolysaccharide. Science 252: 1321-1322.
50. Ramana, C. V., M. Chatterjee-Kishore, H. Nguyen, and G. R. Stark. 2000. Complex roles of Stat1 in regulating gene expression. Oncogene 19: 2619-2627.
51. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
52. + regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J. Exp. Med. 199: 25-34.
53. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95: 7556-7561.
54. Pfeffer, L. M., J. E. Mullersman, S. R. Pfeffer, A. Murti, W. Shi, and C. H. Yang. 1997. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IF-NAR1 chain of the type I interferon receptor. Science 276: 1418-1420.
55. Nguyen, H., C. V. Ramana, J. Bayes, and G. R. Stark. 2001. Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J. Biol. Chem. 276: 33361-33368.
56. Zhang, D. E., C. J. Hetherington, S. Tan, S. E. Dziennis, D. A. Gonzalez, H. M. Chen, and D. G. Tenen. 1994. Sp1 is a critical factor for the monocytic specific expression of human CD14. J. Biol. Chem. 269: 11425-11434.
57. Look, D. C., M. R. Pelletier, R. M. Tidwell, W. T. Roswit, and M. J. Holtzman. 1995. Stat1 depends on transcriptional synergy with Sp1. J. Biol. Chem. 270: 30264-30267.
58. Ouchi, T., S. W. Lee, M. Ouchi, S. A. Aaronson, and C. M. Horvath. 2000. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-γ target genes. Proc. Natl. Acad. Sci. USA 97: 5208-5213.
59. Zhang, J. J., U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and J. E. Darnell, Jr. 1996. Two contact regions between Stat1 and CBP/p300 in interferon-γ signaling. Proc. Natl. Acad. Sci. USA 93: 15092-15096.